TECX Tectonic Therapeutic, Inc.
USHealthcareAs of 2026-08-24
Why TECX matters now
Tectonic Therapeutic, Inc. (TECX) is a US stock in Healthcare. The latest InvestLog snapshot shows $36.39 with -3.31% on the session and $686.6M in market capitalization; recent performance reads 1-month +10.00% and YTD +43.91%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-25.2M, and EPS of $-1.34. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.6%.
The latest indexable market news headline is "Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $75.00; recent insider activity includes Lochner Daniel filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.45
P/S
0.00
EV/EBITDA
-4.15
DCF Value
$13.73
FCF Yield
-11.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.3%
ROA
-33.9%
ROIC
-39.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-25.2M | $-1.34 |
| Q4 2025 | $0.00 | $-19.2M | $-1.03 |
| FY 2025 | $0.00 | $-74.2M | $-4.05 |
| Q3 2025 | $0.00 | $-19.0M | $-1.02 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$72.00
Target (Median)
$75.00
Target Range
$60.00 - $81.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.22
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.